A new report from the American Cancer Association predicts lung cancer will cause more deaths than any other in 2026.

More than 70% of people diagnosed with cancer in the United States now survive for five years or more, a milestone experts ...

First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after progression on prior EGFR-TKI treatment - ...

From January 12 to 15, 2026, the 44th J.P. Morgan Healthcare Conference (JPMHC) was held in San Francisco, California, USA.

The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular ...

Summit Therapeutics has submitted a Biologics License Application to the FDA for ivonescimab, a first-in-class bispecific ...

The dual inhibition of PD-1 and VEGF pathways by ivonescimab aims to enhance immune response and limit tumor angiogenesis, ...

(Alliance News) - Hutchmed China Ltd on Wednesday said the results from its SACHI phase-three lung cancer trial have been published in medical journal the Lancet.

Financial Guidance As of September 30, 2025, cash, cash equivalents and investments totaled $413.0 million, which the company expects will be sufficient to fund its operating plan into 2H 2028, beyond ...

At just 42, a mom of three kids was diagnosed with stage 4 lung cancer, which had already spread to her brains and bones.

Summit Therapeutics Inc. ( SMMT) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 12:45 PM EST ...

TROPION-Lung17 will enroll approximately 400 patients across global sites. Participants are randomized 1:1 to receive either ...